Cardiff Oncology reported that median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus approximately 11 months in combined standard-of-care arms. It is preparing a registrational Phase 3 trial with a potential Q1 2027 start.
CRDF · Cardiff Oncology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that there exists a substantial doubt about our ability to continue as a going concern, see Note 1 Business Organization and Overview - Going Concern Uncertainty to the financial statements for additional details.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients.
Cardiff Oncology appointed Leila Alland, MD, interim Chief Medical Officer on October 23, 2026, succeeding Roger Sidhu, MD, who separated October 22, 2026. The company also increased authorized common stock to 300,000,000 shares.
Cardiff Oncology stockholders approved increasing authorized capital stock from 170,000,000 to 320,000,000 and authorized common stock from 150,000,000 to 300,000,000 at the October 22, 2026 Special Meeting.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRDF
this stock
Cardiff Oncology, Inc.
|
$56.49M | -74.2% | +49.6% | — | 15.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 29
Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRDF | -8.7% | -19.4% | -62.6% | -18.4% | -74.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -11.3% | -18.3% | -63.1% | -18.2% | -84.8% |